AUTHORS
Jinyun Lai, Yue Lu, PhD2, Ruijuan Sun, MD3, Xingyu Cao, MD4, Zhiqiang Sun, MD, PhD5, Zhiping Fan, MD6, Na Xu7, Fen Huang8, Jing Sun, MSc9, Qifa Liu, MD10, Hua Jin11
AFFILIATIONS
1 Nanfang Hospital, Southern Medical University, Guangzhou, China
2 Hebei Yanda Lu Daopei Hospital, Hebei, China
3 Hebei Yanda Lu Daopei Hospital, Hebei, China
4 Hebei Yanda Lu Daopei Hospital, Hebei, China
5 Shenzhen Hospital, Southern Medical University, Shenzhen, China
6 Nanfang Hospital, Southern Medical University, Guangzhou, China
7 Nanfang Hospital, Southern Medical University, Guangzhou, China
8 Nanfang Hospital, Southern Medical University, Guangzhou, China
9 Nanfang Hospital, Southern Medical University, Guangzhou, China
10 Nanfang Hospital, Southern Medical University, Guangzhou, China
11 Nanfang Hospital, Southern Medical University, Guangzhou, China
ABSTRACT
Introduction: Refractory acute graft-versus-host disease (R-aGVHD) remains a leading cause of non-relapse mortality following allogeneic hematopoietic stem cell transplantation. Jaktinib, a broad-spectrum kinase inhibitor targeting the JAK pathway, FLT3, and c-Kit, suppresses key signaling in GVHD pathogenesis. Although it significantly mitigates GVHD and prolongs survival in preclinical mouse models, its clinical efficacy in refractory acute GVHD (R-aGVHD) remains to be defined.
Methods: This multicenter retrospective study involved 28 patients with R-aGVHD. Jaktinib was given orally at a dose of 50 mg twice daily. The median time of follow up was 6.60 months (range, 1.07-13.47). We assessed overall and organ-specific response rates, survival outcomes, and safety profiles.
Result: In total, 28 patients (78.6% male) with a median age of 34 years (range, 15-71) were included in the analysis, and 24 (85.7%) received haploidentical HSCT. Prior to jaktinib, 19 (67.9%) had grade III-IV aGVHD, and 11 (39.3%) had ≥ 2-organ involvement. Overall response at Day 28 was 71.4%(95%CI:51.3%-86.8%), comprising complete responses (CR) in 42.8% of patients. By Day 56, ORR was maintained at 67.9%(95%CI: 47.7%-84.1%), with the CR rate increasing to 57.1%. Day 56 organ-specific ORRs were 100% (13/13) in the skin, 77.8% (7/9) in the liver, 71.4% (5/7) in the upper gastrointestinal (GI) tract, and 50.0% (8/16) in the lower GI tract. The estimated 6-month overall survival (OS) rate was 57.1% (95% CI, 41.5%-78.8%). By Day 56, all evaluable patients (n=21) achieved corticosteroid tapering, with 90.5% (19/21) completely discontinuing therapy. Treatment-emergent adverse events (TEAEs) of grade ≥3 were observed in 17.9% (5/28) of the patients. The most common TEAE was infection (39.3%, 11/28), including CMV (n=3) and EBV (n=2) reactivations.
Conclusion: Jaktinib was effective and well-tolerated in patients with R-aGVHD. Further prospective trials are needed to define Jaktinib’s therapeutic effects and mechanism of action.
DISCLOSURES
Hua Jin: No relevant conflicts of interest to declare.